What Fed. Circ. False Ad Ruling Means For Section 337 Claims
Law360 (May 14, 2019, 4:37 PM EDT) -- In its long-awaited decision in Amarin Pharma. v. U.S. International Trade Commission, the U.S. Court of Appeals for the Federal Circuit provided guidance on the U.S. International Trade Commission’s discretion to decline to institute an investigation under Section 337 of the Tariff Act and the interplay between Section 337 claims and the Food, Drug, and Cosmetics Act — an increasingly common issue at the ITC.
The opinion also addressed the Federal Circuit’s appellate jurisdiction to review the ITC’s noninstitution decisions. Companies that litigate at the ITC, particularly those that manufacture, distribute or import U.S. Food and Drug Administration-regulated products, should be aware...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!
Kirkland & Ellis LLP has redefined what it means to be the biggest of BigLaw — weighing in at 2,116 attorneys by year end 2018 and becoming the first firm since Law360 began tracking law firm head counts to top 2,000 U.S.-based attorneys.